Acceleron Pharma (XLRN) Tops Q4 EPS by 4c

Acceleron Pharma (NASDAQ: XLRN) reported Q4 EPS of ($0.51), $0.04 better than the analyst estimate of ($0.55). Revenue for the quarter came in at $3.37 million versus the consensus estimate of $3.74 million.

For earnings history and earnings-related data on Acceleron Pharma (XLRN) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Calidi Biotherapeutics (CLDI) Reports Q2 Loss of $2.94
• Cheetah Net Supply Chain Service Inc. (CTNT) Reports Q2 EPS of $0.04